After the United States Supreme Court ruling in the Association for Molecular Pathology v. Myriad Genetics in June of 2013, the industry scurried. The Court ruled that naturally occurring DNA is not patent eligible even if isolated, but cDNA or “complementary DNA” is because it is not naturally occurring but rather a product of the laboratory scientist…

Read More